Brief: Lipidor Invests In New Drug Development Project Against Acne Vulgaris

Lipidor AB

17/12/2021 07:35

Dec 17 (Reuters) - Lipidor AB  LIPI.ST :
    * LIPIDOR EXPANDS CLINICAL PROGRAM, ANNOUNCES INVESTMENT IN
NEW
DRUG DEVELOPMENT PROJECT AGAINST ACNE VULGARIS
    * INITIATED A PRECLINICAL PROGRAM FOR A NEW DRUG CANDIDATE,
AKP-08, FOCUSED ON ACNE VULGARIS (ACNE)
    * DEVELOPMENT COSTS FOR AKP-08 ARE FINANCED BY COMPANY'S
EXISTING
LIQUID ASSETS AND REVENUES FROM LICENSE AGREEMENTS.
    * CLINICAL PROGRAM FOR AKP-01 AND AKP-02 IS RUN TOGETHER
WITH
CADILA PHARMACEUTICS AND STUDY RESULTS FOR ONGOING PHASE III
STUDY FOR AKP-02 ARE EXPECTED DURING H1 2022

Source text for Eikon:  ID: 
Further company coverage:  LIPI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))